Prognostic role of inflammatory biomarkers in metastatic breast cancer

被引:1
作者
Petekkaya, Ibrahim [1 ]
Unlu, Ozan [1 ]
Roach, Emir C. [1 ]
Gecmez, Gizem [1 ]
Okoh, Alexis K. [1 ]
Babacan, Taner [1 ]
Sarici, Furkan [1 ]
Keskin, Ozge [1 ]
Arslan, Cagatay [1 ]
Petekkaya, Emine [2 ]
Sever, Ali R. [3 ]
Altundag, Kadri [1 ]
机构
[1] Hacettepe Univ, Canc Inst, Dept Med Oncol, TR-06100 Ankara, Turkey
[2] Zirve Univ, EBN Sch Med, Dept Anat, Gaziantep, Turkey
[3] Hacettepe Univ, Sch Med, Dept Radiol, Ankara, Turkey
来源
JOURNAL OF BUON | 2017年 / 22卷 / 03期
关键词
breast cancer; inflammatory markers; metastasis; parameter; prognosis; C-REACTIVE PROTEIN; SERUM-ALBUMIN; SURVIVAL; BETA-2-MICROGLOBULIN; DISEASE; CELLS; SCORE; IRON;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The effects of inflammation on the prognosis, life expectancy and several parameters such as response to treatment of breast cancer have been previously studied. The purpose of this study was to investigate the effect of inflammatory markers on prognosis in patients with metastatic breast cancer. Methods: This study was conducted on 81 patients with metastatic breast cancer who have been followed up at the Department of Medical Oncology, Hacettepe University Institute of Oncology, between December, 2009 and March, 2014. For all studied parameters Kaplan-Meier survival estimates and p values computed by log-rank test were calculated. A p value <0.05 was considered statistically significant. Results: Median follow-up time was 26 months. There were 38 deaths due to disease progression during the follow up. The levels of serum albumin, and erythrocyte sedimentation rate (ESR) were not associated with a significant effect on overall survival (OS). Among patients with a higher serum C-reactive protein (CRP), the estimated mean survival was 84 +/- 36 months, compared to 278 +/- 113 months among patients with a normal serum CRP (p=0.032). When patients with higher and normal lactate dehydrogenase (LDH) levels were compared, their 2-year OS survival rates were 68.2 and 87.7%, respectively (p =0.034). Among patients with higher serum ferritin levels, the estimated mean survival was 29 +/- 10 months, compared to 212 +/- 113 months for normal serum ferritin (p=0.01). Among patients with higher serum beta-2 microglobulin beta 2-m, the estimated mean OS survival was 28 +/- 8 months, compared to 84 +/- 57 months for those with normal levels (p<0.01). Conclusion: Serum CRP ferritin and)beta 2-M can be useful prognostic factors for OS in patients with metastatic breast cancer.
引用
收藏
页码:614 / 622
页数:9
相关论文
共 50 条
[41]   Role of Loco-regional Surgery in metastatic breast cancer [J].
Deo, S. V. Suryanarayana ;
Jha, Deepak .
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2013, 9 (02) :181-186
[42]   Prognostic role of YB-1 expression in breast cancer: a meta-analysis [J].
Wang, Xu ;
Guo, Xiao-Bo ;
Shen, Xiao-Chun ;
Zhou, Hao ;
Wan, Dan-Wei ;
Xue, Xiao-Feng ;
Han, Ye ;
Yuan, Bin ;
Zhou, Jin ;
Zhao, Hong ;
Zhi, Qiao-Ming ;
Kuang, Yu-Ting .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (02) :1780-1791
[43]   HOTAIR: a potential metastatic, drug-resistant and prognostic regulator of breast cancer [J].
Ganji Seeta Rama Raju ;
Eluri Pavitra ;
Sai Samyuktha Bandaru ;
Ganji Lakshmi Varaprasad ;
Ganji Purnachandra Nagaraju ;
Rama Rao Malla ;
Yun Suk Huh ;
Young-Kyu Han .
Molecular Cancer, 22
[44]   Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer [J].
Peng, Cike ;
Wallwiener, Markus ;
Rudolph, Anja ;
Cuk, Katarina ;
Eilber, Ursula ;
Celik, Muhabbet ;
Modugno, Caroline ;
Trumpp, Andreas ;
Heil, Joerg ;
Marme, Frederik ;
Madhavan, Dharanija ;
Nees, Juliane ;
Riethdorf, Sabine ;
Schott, Sarah ;
Sohn, Christof ;
Pantel, Klaus ;
Schneeweiss, Andreas ;
Chang-Claude, Jenny ;
Yang, Rongxi ;
Burwinkel, Barbara .
INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (10) :2499-2509
[45]   Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases [J].
Parkes, Amanda ;
Warneke, Carla L. ;
Clifton, Katherine ;
Al-Awadhi, Aydah ;
Oke, Oluchi ;
Pestana, Roberto Carmagnani ;
Alhalabi, Omar ;
Litton, Jennifer K. ;
Hortobagyi, Gabriel N. .
ONCOLOGIST, 2018, 23 (11) :1282-1288
[46]   The prognostic role of a combined fibrinogen and inflammation-based index in patients with metastatic breast cancer [J].
Liu, Qiuge ;
Fang, Shuangshuang ;
Liang, Shanshan ;
Lv, Jinyan ;
Wang, Gang ;
Tang, Rongbin ;
Ji, Xuening ;
Zhao, Tong ;
Li, Jiaoyang ;
Xu, Lu ;
Ma, Lianli ;
Wang, Ruoyu ;
Li, Heming .
TRANSLATIONAL CANCER RESEARCH, 2020, 9 (11) :7065-7078
[47]   Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial [J].
Gardini, Andrea Casadei ;
Scarpi, Emanuela ;
Valgiusti, Martina ;
Monti, Manlio ;
Ruscelli, Silvia ;
Matteucci, Laura ;
Bartolini, Giulia ;
Vertogen, Bernadette ;
Pagan, Flavia ;
Rovesti, Giulia ;
Frassineti, Giovanni Luca ;
Passardi, Alessandro .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
[48]   Prognostic Value Of Preoperative Systemic Inflammatory Biomarkers In Patients With Gallbladder Cancer And The Establishment Of A Nomogram [J].
Deng, Yan ;
Zhang, Feng ;
Yu, Xiao ;
Huo, Cheng-Long ;
Sun, Zhen-Gang ;
Wang, Shuai .
CANCER MANAGEMENT AND RESEARCH, 2019, 11 :9025-9035
[49]   The role and indications of aggressive locoregional therapy in metastatic inflammatory breast cancer [J].
Yan, Yi ;
Tang, Lili ;
Tong, Wei ;
Zhou, Jingyu .
SCIENTIFIC REPORTS, 2016, 6
[50]   Metastatic breast cancer induces an osteoblast inflammatory response [J].
Kinder, Michelle ;
Chislock, Elizabeth ;
Bussard, Karen M. ;
Shuman, Laurie ;
Mastro, Andrea M. .
EXPERIMENTAL CELL RESEARCH, 2008, 314 (01) :173-183